RESEARCH PAPER Anti-apoptotic effects of protein kinase C-d and c-fos in cisplatin-treated thyroid cells

[1]  K. Jiang,et al.  Identification of a novel antiapoptotic human protein kinase C delta isoform, PKCdeltaVIII in NT2 cells. , 2008, Biochemistry.

[2]  Nizar M. Mhaidat,et al.  Regulation of Docetaxel-Induced Apoptosis of Human Melanoma Cells by Different Isoforms of Protein Kinase C , 2007, Molecular Cancer Research.

[3]  L. Forman,et al.  Protein Kinase Cδ Is Required for Survival of Cells Expressing Activated p21RAS* , 2007, Journal of Biological Chemistry.

[4]  D. Migoni,et al.  Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment. , 2005, Biochemical pharmacology.

[5]  D. Migoni,et al.  Differential functions of PKC-δ and PKC-ζ in cisplatin response of normal and transformed thyroid cells , 2005 .

[6]  A. Basu,et al.  Activation of ERK during DNA damage-induced apoptosis involves protein kinase Cdelta. , 2005, Biochemical and biophysical research communications.

[7]  M. Yuen,et al.  Antisense Targeting Protein Kinase C α and β1 Inhibits Gastric Carcinogenesis , 2004, Cancer Research.

[8]  Jie Huang,et al.  Cisplatin resistance is associated with deregulation in protein kinase C-delta. , 2004, Biochemical and biophysical research communications.

[9]  A. Muscella,et al.  Angiotensin II AT1 receptor stimulates Na+–k+atpase activity through a pathway involving pkc‐ζ in rat thyroid cells , 2003, The Journal of physiology.

[10]  David Polsky,et al.  Focus on melanoma. , 2002, Cancer cell.

[11]  I. Weinstein,et al.  Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-β1-dependent pathway , 2002, Oncogene.

[12]  C. Harmer,et al.  Management of thyroid cancer. , 2002, The Lancet. Oncology.

[13]  Kathleen E. Sullivan,et al.  A role for PKC-δ and PI 3-kinase in TNF-α-mediated antiapoptotic signaling in the human neutrophil , 2002 .

[14]  P. Blumberg,et al.  Infection of Glioma Cells with Sindbis Virus Induces Selective Activation and Tyrosine Phosphorylation of Protein Kinase C δ , 2002, The Journal of Biological Chemistry.

[15]  K. Yeh,et al.  Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. , 2002, Biochemical pharmacology.

[16]  M. Kitazawa,et al.  Caspase-3-Dependent Proteolytic Cleavage of Protein Kinase Cδ Is Essential for Oxidative Stress-Mediated Dopaminergic Cell Death after Exposure to Methylcyclopentadienyl Manganese Tricarbonyl , 2002, The Journal of Neuroscience.

[17]  J. Peluso,et al.  Basic Fibroblast Growth Factor Maintains Calcium Homeostasis and Granulosa Cell Viability by Stimulating Calcium Efflux via a PKCδ-Dependent Pathway. , 2001, Endocrinology.

[18]  J. Quivey,et al.  Completely resected anaplastic thyroid carcinoma combined with adjuvant chemotherapy and irradiation is associated with prolonged survival , 2001, Cancer.

[19]  J. Hansson,et al.  The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis , 2001, Melanoma research.

[20]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[21]  H. Palfrey,et al.  Divergence in the anti-apoptotic signalling pathways used by nerve growth factor and basic fibroblast growth factor (bFGF) in PC12 cells: rescue by bFGF involves protein kinase C delta. , 2000, The Biochemical journal.

[22]  P. Haigh.  Anaplastic thyroid carcinoma , 2000, Current treatment options in oncology.

[23]  A. Grothey,et al.  Cisplatin resistance and oncogenes - a review , 2000, Anti-cancer drugs.

[24]  B. C. Wong,et al.  Overexpression of protein kinase C-beta1 isoenzyme suppresses indomethacin-induced apoptosis in gastric epithelial cells. , 2000, Gastroenterology.

[25]  G. Singh,et al.  Influence of the proto-oncogene c-fos on cisplatin sensitivity. , 2000, Biochemical pharmacology.

[26]  H. Grunicke,et al.  The involvement of protein kinase C isoenzymes alpha, epsilon and zeta in the sensitivity to antitumor treatment and apoptosis induction. , 1999, Anticancer research.

[27]  E. Yazlovitskaya,et al.  Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  A. Basu,et al.  Regulation of caspase activation and cis-diamminedichloroplatinum(II)-induced cell death by protein kinase C. , 1999, Biochemistry.

[29]  R. Park,et al.  Overexpression of protein kinase C isoforms protects RAW 264.7 macrophages from nitric oxide-induced apoptosis: involvement of c-Jun N-terminal kinase/stress-activated protein kinase, p38 kinase, and CPP-32 protease pathways. , 1999, Journal of immunology.

[30]  P. Parker,et al.  Loss of protein kinase C function induces an apoptotic response , 1998, Oncogene.

[31]  S. Haas,et al.  A general role for c-Fos in cellular protection against DNA-damaging carcinogens and cytostatic drugs. , 1997, Cancer research.

[32]  M. Monden,et al.  Chemosensitivity of anaplastic thyroid carcinoma and poorly differentiated thyroid carcinoma. , 1997, Anticancer research.

[33]  D. Mochly‐Rosen,et al.  Translocation Inhibitors Define Specificity of Protein Kinase C Isoenzymes in Pancreatic β-Cells* , 1997, The Journal of Biological Chemistry.

[34]  S. Ratnofsky,et al.  Proteolytic Activation of Protein Kinase C δ by an ICE/CED 3-like Protease Induces Characteristics of Apoptosis , 1996, The Journal of experimental medicine.

[35]  C. Arteaga,et al.  Tissue-targeted antisense c-fos retroviral vector inhibits established breast cancer xenografts in nude mice. , 1996, Cancer research.

[36]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[37]  Philip R. Cohen,et al.  PD 098059 Is a Specific Inhibitor of the Activation of Mitogen-activated Protein Kinase Kinase in Vitro and in Vivo(*) , 1995, The Journal of Biological Chemistry.

[38]  S. Akiyama,et al.  Expression of multidrug resistance-associated protein (MRP) in thyroid cancers. , 1995, Cancer letters.

[39]  E. Nishida,et al.  Signaling pathways mediated by the mitogen‐activated protein (MAP) kinase kinase/MAP kinase cascade , 1994, Journal of leukocyte biology.

[40]  M. Zou,et al.  p53 mutations in all stages of thyroid carcinomas. , 1993, The Journal of clinical endocrinology and metabolism.

[41]  G. Martiny-Baron,et al.  Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. , 1993, The Journal of biological chemistry.

[42]  R. Bravo,et al.  Existence of different Fos/Jun complexes during the G0-to-G1 transition and during exponential growth in mouse fibroblasts: differential role of Fos proteins , 1992, Molecular and cellular biology.

[43]  P. Cerutti,et al.  Mechanism of c-fos induction by active oxygen. , 1992, Cancer research.

[44]  S. Kochhar,et al.  Primary structure, physicochemical properties, and chemical modification of NAD(+)-dependent D-lactate dehydrogenase. Evidence for the presence of Arg-235, His-303, Tyr-101, and Trp-19 at or near the active site. , 1992, The Journal of biological chemistry.

[45]  A. Thor,et al.  Ras oncogene mutations in benign and malignant thyroid neoplasms. , 1991, The Journal of clinical endocrinology and metabolism.

[46]  K. Scanlon,et al.  Cyclosporin A suppresses cisplatin-induced oncogene expression in human cancer cells. , 1990, Cancer treatment reviews.

[47]  M. Kashani-Sabet,et al.  Cyclosporin A suppresses cisplatin-induced c-fos gene expression in ovarian carcinoma cells. , 1990, The Journal of biological chemistry.

[48]  D. Scudiero,et al.  New colorimetric cytotoxicity assay for anticancer-drug screening. , 1990, Journal of the National Cancer Institute.

[49]  M. Kashani-Sabet,et al.  Molecular basis of cisplatin resistance in human carcinomas: model systems and patients. , 1989, Anticancer research.

[50]  A. Fornace,et al.  Induction of fos RNA by DNA-damaging agents. , 1989, Cancer research.

[51]  T. Hunter,et al.  The c-fos protein interacts with c-Jun AP-1 to stimulate transcription of AP-1 responsive genes , 1988, Cell.

[52]  J. Lillehaug,et al.  Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB. , 1988, British Journal of Cancer.

[53]  P. Terrier,et al.  Structure and expression of c-myc and c-fos proto-oncogenes in thyroid carcinomas. , 1988, British Journal of Cancer.

[54]  A. Fusco,et al.  One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes , 1987, Molecular and cellular biology.

[55]  N. Patel,et al.  PKCδ Alternatively Spliced Isoforms Modulate Cellular Apoptosis in Retinoic Acid-Induced Differentiation of Human NT2 Cells and Mouse Embryonic Stem Cells , 2006 .

[56]  M. Olive,et al.  Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines , 2002, Cancer Gene Therapy.

[57]  D. Hinshaw,et al.  Granulocyte-macrophage colony-stimulating factor rescues human polymorphonuclear leukocytes from ultraviolet irradiation-accelerated apoptosis. , 1999, The Journal of surgical research.

[58]  N. Hanna,et al.  Advances in the pathogenesis and treatment of thyroid cancer. , 1999, Current opinion in oncology.

[59]  M. Kashani-Sabet,et al.  The Role of the c-fos Oncogene in Cisplatin Resistance , 1991 .

[60]  J. G. Nørby.  [11] Coupled assay of Na+,K+-ATPase activity , 1988 .